Dickran Kazandjian

Dr. Dickran Kazandjian

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Seminars in Oncology
Verified
Journal Article
Open access
DKDickran Kazandjian
Dickran Kazandjian
Multiple myeloma (MM), although a rare disease, is the second most common hematologic malignancy. It is found in the spectrum of plasma cell dyscrasias, which begins with monoclonal gammopathy of unknown significance (MGUS) to overt plasma cell leukemia and extramedullary myeloma. MM is associated with significant morbidity due to its end-organ destruction. It is a disease of the older population and its incidence in the African American population is twice that of the European American population. Improvements in the treatment of MM in the past couple of decades, beginning with the use of autologous stem cell transplantation followed by availability of novel treatments such as immunomodulatory drugs (ImIDs) and proteasome inhibitors (PIs) has transformed the natural history of the disease leading to longer survival times. Advancements in the diagnosis, monitoring, and treatment of MM are of the utmost importance as the general population lives longer due to other improvements in health care. The recent introduction of novel therapies has been paralleled by advancements in the monitoring of MM, namely, by the availability exquisitely sensitive techniques in detecting minimal residual disease. As drug development and technology continues to improve, it will be important to design rationale clinical trials enrolling patient populations that represent the overall population, including racial minorities and the elderly, so that trial results can be appropriately extrapolated. Herein, the changing epidemiology, improvements in survival, and the health disparity observed in important subgroups of MM are reviewed.

10 April 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
FMFrancesco Maura
Francesco Maura
ARArjun Raj Rajanna
Arjun Raj Rajanna
BZBachisio Ziccheddu
Bachisio Ziccheddu
APAlexandra M. Poos
Alexandra M. Poos
ADAndriy Derkach
Andriy Derkach
OLOla Landgren
Ola Landgren
PURPOSE: Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS: To decipher and predict the molecular and clinical heterogeneity of NDMM, we assembled a series of 1,933 patients with available clinical, genomic, and therapeutic data. RESULTS: Leveraging a comprehensive catalog of genomic drivers, we identified 12 groups, expanding on previous gene expression–based molecular classifications. To build a model predicting individualized risk in NDMM (IRMMa), we integrated clinical, genomic, and treatment variables. To correct for time-dependent variables, including high-dose melphalan followed by autologous stem-cell transplantation (HDM-ASCT), and maintenance therapy, a multi-state model was designed. The IRMMa model accuracy was significantly higher than all comparator prognostic models, with a c-index for OS of 0.726, compared with International Staging System (ISS; 0.61), revised-ISS (0.572), and R2-ISS (0.625). Integral to model accuracy was 20 genomic features, including 1q21 gain/amp, del 1p, TP53 loss, NSD2 translocations, APOBEC mutational signatures, and copy-number signatures (reflecting the complex structural variant chromothripsis). IRMMa accuracy and superiority compared with other prognostic models were validated on 256 patients enrolled in the GMMG-HD6 (ClinicalTrials.gov identifier: NCT02495922 ) clinical trial. Individualized patient risks were significantly affected across the 12 genomic groups by different treatment strategies (ie, treatment variance), which was used to identify patients for whom HDM-ASCT is particularly effective versus patients for whom the impact is limited. CONCLUSION: Integrating clinical, demographic, genomic, and therapeutic data, to our knowledge, we have developed the first individualized risk-prediction model enabling personally tailored therapeutic decisions for patients with NDMM.

9 November 2023 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
FMFrancesco Maura
Francesco Maura
EBEileen M. Boyle
Eileen M. Boyle
DCDavid Coffey
David Coffey
KMKylee Maclachlan
Kylee Maclachlan
DGDylan Gagler
Dylan Gagler
OLOla Landgren
Ola Landgren

1 December 2016 in Seminars in Oncology
Verified
Journal Article
Open access
DKDickran Kazandjian
Dickran Kazandjian
OLOla Landgren
Ola Landgren
The past decade has seen significant advances in our understanding and treatment of multiple myeloma (MM) and its precursor diseases. These advances include gains in knowledge of the underlying pathobiology including molecular and cellular prognostic factors for disease progression. In parallel we have witnessed the availability of novel therapeutics. Together these advances have translated into improvements in long-term clinical benefit and survival in MM. Indeed, it has been shown that patients diagnosed in the last decade have experienced almost doubling of median survival time. We aim to review and give further insight into drug development and novel drug approvals that have revolutionized the treatment of MM.

16 September 2021 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
DKDickran Kazandjian
Dickran Kazandjian
EHElizabeth Hill
Elizabeth Hill
ADAlexander Dew
Alexander Dew
CMCandis Morrison
Candis Morrison
JRJoseph Roswarski
Joseph Roswarski
OLOla Landgren
Ola Landgren
Multiple myeloma is characterized by the proliferation and accumulation of malignant plasma cells in the bone marrow and has been shown to be preceded by the premalignant states of either monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma.1 Currently, markers that predict progression to multiple myeloma are dependent on clinical variables that are influenced by the timing of diagnosis. Moreover, it was recently shown that the risk of progression is dynamic, with evolving risk patterns supporting close follow-up of patients.2 Smoldering myeloma has a risk of progression that is higher than that of MGUS and can be risk stratified using the Mayo Clinic, Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA), and/or the criteria set forth by Rajkumar, Landgren, and Mateos.3-7 Using these risk models, patients with high-risk smoldering myeloma have an approximately 75% risk of developing symptomatic multiple myeloma at 5 years and a median time to progression of less than 2 years.

2 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
DCDavid G. Coffey
David G. Coffey
FMFrancesco Maura
Francesco Maura
EGEdgar Gonzalez-Kozlova
Edgar Gonzalez-Kozlova
JDJ. Javier Diaz-Mejia
J. Javier Diaz-Mejia
PLPing Luo
Ping Luo
OLOla Landgren
Ola Landgren
The role of the immune microenvironment in maintaining disease remission in patients with multiple myeloma (MM) is not well understood. In this study, we comprehensively profile the immune system in patients with newly diagnosed MM receiving continuous lenalidomide maintenance therapy with the aim of discovering correlates of long-term treatment response. Leveraging single-cell RNA sequencing and T cell receptor β sequencing of the peripheral blood and CyTOF mass cytometry of the bone marrow, we longitudinally characterize the immune landscape in 23 patients before and one year after lenalidomide exposure. We compare patients achieving sustained minimal residual disease (MRD) negativity to patients who never achieved or were unable to maintain MRD negativity. We observe that the composition of the immune microenvironment in both the blood and the marrow varied substantially according to both MRD negative status and history of autologous stem cell transplant, supporting the hypothesis that the immune microenvironment influences the depth and duration of treatment response.